» Articles » PMID: 17315165

Radical Prostatectomy for Clinical Stage T3a Disease

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2007 Feb 23
PMID 17315165
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Men with clinical stage T3a disease are at high risk and are often encouraged to undergo radiation therapy with concomitant hormonal therapy. The long-term outcomes among men treated with radical prostatectomy for clinical stage T3a disease were examined.

Methods: Among 3397 men treated by radical prostatectomy by 1 surgeon between 1987 and 2003, 62 (1.8%) men were identified who had clinical stage T3a disease. Among the 56 men not treated with neoadjuvant or adjuvant therapies before prostate-specific antigen (PSA) recurrence, the long-term outcomes of PSA-free survival, metastasis-free survival, and prostate cancer specific survival were examined. Median and mean follow-up after surgery were 10.3 and 13 years, respectively (range, 1-17).

Results: Ninety-one percent of men in this group had pathological T3 disease. PSA-free survival at 15 years after surgery was 49%. Metastasis-free survival and cause-specific survival at 15 years after surgery were 73% and 84%, respectively. Among men with a PSA recurrence, 46% received secondary therapy before metastasis. The only preoperative or pathological feature that predicted risk of prostate cancer death was lymph node metastasis (hazard ratio [HR]: 9.22, 95% confidence interval [CI]: 1.06-80.02, P = .044). Among the 28 men with a PSA recurrence, PSA doubling time (PSADT) data were available for 23, of which 11 (48%) has a PSADT >/=9 months. No patient with a PSADT >/=9 months died of prostate cancer. A PSADT <9 months was significantly associated with increased risk of prostate cancer death (log-rank, P = .004).

Conclusions: In a select cohort of men with clinical stage T3a disease, radical prostatectomy alone provides long-term cancer control in about half of the men and results in a prostate cancer-specific survival of 84%. Among men with a PSA recurrence, PSADT at the time of recurrence is a useful determinant of risk of prostate cancer death.

Citing Articles

Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study.

El-Karak F, Shamseddine A, Omar A, Haddad I, Abdelgawad M, Naqqash M Ecancermedicalscience. 2024; 18:1695.

PMID: 38774566 PMC: 11108050. DOI: 10.3332/ecancer.2024.1695.


Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.

Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y Life (Basel). 2023; 13(5).

PMID: 37240717 PMC: 10223720. DOI: 10.3390/life13051072.


Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.

Sjoberg H, Philippou Y, Magnussen A, Tullis I, Bridges E, Chatrian A Br J Cancer. 2021; 125(4):534-546.

PMID: 34155340 PMC: 8367986. DOI: 10.1038/s41416-021-01450-6.


A Surveillance, Epidemiology and End Results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma.

Deng Y, Bi R, Zhu Z, Li S, Xu B, Rather W Oncol Lett. 2019; 18(2):1057-1070.

PMID: 31423166 PMC: 6607368. DOI: 10.3892/ol.2019.10461.


Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.

Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S Cancer. 2018; 124(20):4010-4022.

PMID: 30252932 PMC: 6234085. DOI: 10.1002/cncr.31726.